Description: Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Home Page: nykode.com
Oslo Research Park
Oslo,
0349
Norway
Phone:
47 22 95 81 93
Officers
| Name | Title |
|---|---|
| Mr. Michael Thyring Engsig | Chief Executive Officer |
| Mr. Harald Gurvin | Chief Financial Officer |
| Mr. Ulrich Blaschke | Chief Technology Officer |
| Dr. Agnete B. Fredriksen Ph.D. | Chief Scientific Officer & Business Development |
| Ms. Louise Stubbe | Chief Legal Officer |
| Dr. Klaus Edvardsen M.D., Ph.D. | Chief Research & Development Officer |
Exchange: OL
Country: NO : Norway
Currency: Norwegian Krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.592 |
| Price-to-Sales TTM: | 143.3274 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 179 |